Recent studies have demonstrated that HER2-positive breast cancer patients with elevated levels of circCDYL2 experience rapid recurrence after anti-HER2 therapy compared with those with lower levels of circCDYL2. This evidence concerns the gene ERBB2 and breast carcinoma.